These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Systemic chemotherapy for advanced bladder cancer: update and controversies. Garcia JA; Dreicer R J Clin Oncol; 2006 Dec; 24(35):5545-51. PubMed ID: 17158540 [TBL] [Abstract][Full Text] [Related]
26. Management of advanced bladder cancer in patients with impaired renal function. Bournakis E; Dimopoulos MA; Bamias A Expert Rev Anticancer Ther; 2011 Jun; 11(6):931-9. PubMed ID: 21707290 [TBL] [Abstract][Full Text] [Related]
27. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Small EJ; Halabi S; Dalbagni G; Pruthi R; Phillips G; Edelman M; Bajorin D; Cancer; 2003 Apr; 97(8 Suppl):2090-8. PubMed ID: 12673701 [TBL] [Abstract][Full Text] [Related]
28. Progress in the chemotherapy of metastatic cancer of the urinary tract. Raghavan D Cancer; 2003 Apr; 97(8 Suppl):2050-5. PubMed ID: 12673696 [TBL] [Abstract][Full Text] [Related]
30. [Chemotherapy of bladder carcinoma. Current status and trends]. Block T Urologe A; 1994 Nov; 33(6):557-67. PubMed ID: 7817457 [TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer. Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818 [TBL] [Abstract][Full Text] [Related]
32. The role of taxanes in the management of bladder cancer. Galsky MD Oncologist; 2005; 10(10):792-8. PubMed ID: 16314289 [TBL] [Abstract][Full Text] [Related]
33. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma. Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009 [TBL] [Abstract][Full Text] [Related]
34. Chemotherapy as an adjuvant to cystectomy and for advanced urothelial cancer. Loening S Urol Clin North Am; 1984 Nov; 11(4):699-708. PubMed ID: 6390915 [TBL] [Abstract][Full Text] [Related]
35. Systemic therapy of bladder cancer. Salem PA Prog Clin Biol Res; 1984; 162B():95-105. PubMed ID: 6209726 [No Abstract] [Full Text] [Related]
36. Current chemotherapeutic options for the treatment of advanced bladder cancer: a review. Pliarchopoulou K; Laschos K; Pectasides D Urol Oncol; 2013 Apr; 31(3):294-302. PubMed ID: 20843708 [TBL] [Abstract][Full Text] [Related]
37. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Aparicio AM; Elkhouiery AB; Quinn DI Urol Clin North Am; 2005 May; 32(2):217-30, vii. PubMed ID: 15862619 [TBL] [Abstract][Full Text] [Related]
38. Management of disseminated disease in the patient with bladder cancer. Perry JJ; Muss HB Urol Clin North Am; 1994 Nov; 21(4):661-72. PubMed ID: 7974898 [TBL] [Abstract][Full Text] [Related]
39. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Audenet F; Yates DR; Cussenot O; Rouprêt M Urol Oncol; 2013 May; 31(4):407-13. PubMed ID: 20884249 [TBL] [Abstract][Full Text] [Related]